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Summary
Introduction Perthes disease is idiopathic avascular osteonecrosis of the hip in children, with unknown 
etiology. Inflammation is present during development of Perthes disease and it is known that this proc-
ess influences bone remodeling.
Objective Since genetic studies related to inflammation have not been performed in Perthes disease 
so far, the aim of this study was to analyze the association of frequencies of genetic variants of immune 
response genes, toll-like receptor 4 (TLR4) and interleukin-6 (IL-6), with this disease.
methods The study cohort consisted of 37 patients with Perthes disease and 50 healthy controls. Poly-
morphisms of well described inflammatory mediators: TLR4 (Asp299Gly, Thr399Ile) and IL-6 (G-174C, G-
597A) were determined by polymerase chain reaction restriction fragment length polymorphism method.
results IL-6 G-174C and G-597A polymorphisms were in complete linkage disequilibrium. A statistically 
significant increase of heterozygote subjects for IL-6 G-174C/G-597A was found in controls in comparison 
to Perthes patient group (p=0.047, OR=2.49, 95% CI=1.00-6.21). Also, the patient group for IL-6 G-174C/G-
597A polymorphisms was not in Hardy-Weinberg equilibrium. No statistically significant differences were 
found between patient and control groups for TLR4 analyzed polymorphisms. A stratified analysis by 
the age at disease onset also did not reveal any significant difference for all analyzed polymorphisms.
Conclusion Our study revealed that heterozygote subjects for the IL-6 G-174C/G-597A polymorphisms 
were significantly overrepresented in the control group than in the Perthes patient group. Consequently, 
we concluded that children who are heterozygous for these polymorphisms have a lower chance of 
developing Perthes disease than carriers of both homozygote genotypes.
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INTrODuCTION
Perthes disease is idiopathic avascular necro-
sis of the femoral head in childhood. It affects 
children between 2 and 14 years old, the male-
to-female ratio is approximately 4:1, and bi-
lateral disease occurs in 10 to 20% of patients 
[1, 2]. This disease belongs to a group of rare 
diseases with the prevalence ranging from 5.1 
to 16.9 per 100,000 in various regions of the 
world [3, 4, 5]. Treatment depends on the age 
of the child and the severity of the condition, 
and may include surgery [6, 7].
Perthes disease remains one of the most 
controversial conditions in pediatric orthoped-
ics, since both the etiology and pathophysiolo-
gy of the disease remain unclear. The prevailing 
view is that Perthes disease is multifactorial, 
caused by a combination of environmental and 
genetic factors. A number of possible causes 
have been proposed, including repetitive mi-
crotrauma, skeletal retardation, inflammation 
and vascular insufficiency [1].
There is not much research about the role 
of inflammatory factors in the pathophysiol-
ogy of Perthes disease, despite the fact that in-
flammatory changes were noticed in magnetic 
resonance studies long ago [8]. The majority 
of those changes are marked during the initial 
phase, as well as during fragmentation phase 
when bone resorption and bone formation are 
uncoupled [8, 9, 10]. The link between bone re-
modeling and cytokine level came from studies 
of other systemic and joint bone diseases, like 
rheumatoid arthritis [11], osteoporosis [12] and 
osteonecrosis of the femoral head [13], illustrat-
ing that high levels of inflammatory mediators 
in affected joint can inhibit bone formation.
OBJECTIVE
We assumed that the development of Perthes 
disease could be associated with the presence 
of polymorphisms in immune response genes, 
which also has the key role in bone metabo-
lism. Therefore, the objective of this study was 
to analyze the frequency of single nucleotide 
polymorphisms (SNPs) of well described in-
flammatory mediators, toll-like receptor 4 
(TLR4) and interleukin-6 (IL-6) in Perthes 
patients.     
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mETHODS
Patients and control subjects
Our study was conducted according to the guidelines of 
the Helsinki Declaration and was also approved by the 
Ethics Committee of the Institute for Orthopedic Surgery 
“Banjica”, Belgrade, Serbia. Written informed consent was 
obtained for all patients.
This study enrolled 37 patients and 50 healthy con-
trols, from the same geographic area. The patient group 
consisted of 29 males and 8 females with a median age at 
disease onset being 5 (range: 2-11) years. Blood collec-
tion was performed at the time of surgery for 17 patients, 
and for the rest of them during control examination. The 
healthy control group was sex matched and all controls 
were older than 14 years, therefore could not develop Per-
thes disease in future. The control group included 35 male 
and 15 female voluntary donors, with a median age 31.5 
(range: 16-53) years.
All patients were diagnosed with Perthes disease from 
1998-2012, at the Institute of Orthopedic Surgery “Ban-
jica”, Belgrade. The diagnosis was established according 
to the standard clinical criteria (onset of groin pain, dis-
turbed stance on affected leg and gait, limitation of hip 
joint movements, especially internal rotation, absence of 
clinical signs suggesting trauma or infection), ultrasono-
graphic examination (verification of homogenous hip joint 
effusion) and radiographic signs (condensation or frag-
mentation of epiphyseal ossification center, loss of femoral 
head sphericity). The left hip was affected in 19, right in 
16 and both in 2 patients. They were all treated in hospital 
by containment method; five were treated conservatively 
by skin traction, and other were operated on using various 
methods (Salter osteotomy in 28 patients including two 
operated on bilaterally, Chiari osteotomy in three patients 
and triple pelvic osteotomy in one patient), depending on 
their age as well as the duration and severity of disease.
DNa isolation
Genomic DNA was isolated from peripheral blood with 
QIAampDNA Mini Kit (Qiagen GmbH, Hilden, Germa-
ny), and stored at -20°C.
Gene variants detection
All analyzed polymorphisms and primers used for their 
detection, are shown in Table 1. Polymorphisms are de-
noted by both, common nomenclature (used through the 
entire article), and HGVS nomenclature.
Toll-like receptor 4 asp299Gly and  
Thr399Ile detection
Polymorphisms Asp299Gly (rs4986790) and Thr399Ile 
(rs4986791) in TLR4 gene were detected by a polymer-
ase chain reaction restriction fragment length polymor-
phism (PCR-RFLP) method as previously described [14]. 
In both cases, the forward primer sequences were altered 
to generate a restriction site in the minor allele. The bases 
that are underlined indicate altered nucleotides that cre-
ate Nco I (Asp299Gly) or Hinf I (Thr399Ile) restriction 
sites, respectively. The amplification program consisted of 
a denaturation step at 94°C for 5 min followed by 35 cycles 
(94°C for 30 sec, 55°C for 30 sec and 72°C for 45 sec) and 
an elongation step of 10 min at 72°C. Digestion with Nco 
I (MBI Fermentas, Vilnius, Lithuania) gave fragments of 
the following length (in base pairs): Asp/Asp-275, Asp/
Gly- 275+249+26, Gly/Gly- 249+26, while digestion with 
Hinf I (MBI Fermentas, Vilnius, Lithuania) gave for Thr/
Thr - 407, Thr/Ile- 407+379+29 and Ile/Ile- 379+29.
Interleukin-6 G-174C and G-597a detection
The genotyping of the polymorphisms in IL-6 promoter 
G-174C (rs1800795) and G-597A (rs1800797) was per-
formed using PCR-RFLP technique as previously de-
scribed [15]. A 527-bp fragment containing both poly-
morphic sites (-597 and -174) was amplified using one 
primer set. The PCR conditions were: denaturation step at 
94°C for 5 min, 35 cycles of amplification (94°C for 30 sec, 
57°C for 30 sec and 72°C for 45 sec) and elongation step of 
10 min at 72°C. The obtained PCR product was digested 
with Hin1 II and Fok I (MBI Fermentas, Vilnius, Lithua-
nia). Digestion with Hin1 II (G-174C) gave the follow-
ing pattern (in base pairs): 331+167+29 for GG genotype, 
331+167+29+122+45 for GC genotype and 331+122+45 
for CC genotype. Digestion with Fok I (G-597A) gave 
fragments of the following length (in base pairs): 527 for 
Table 1. Polymorphisms and primers for genotyping
Gene
Polymorphism
Primers: in 5’-3’ direction
Common nomenclature HGVS nomenclature
TLR4
Asp299Gly NP_612564.1:p.Asp299Gly/
NM_138554.4:c.896A>G
F: GATTAGCATACTTAGACTACTACCTCCATG
R: GATCAACCTTCTGAAAAGCATTCCCAC
Thr399Ile NP_612564.1:p.Thr399Ile/
NM_138557.2:c.596C>T
F: GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA
R: ACCTGAAGACTGGAGAGTGAGTTAAATGCT
IL-6
G-174C NC_000007.13:g.22766645C>G/
NM_000600.3:c.-116-121C>G F: GGAGTCACACACTCCACCT
R: CTGATTGGAAACCTTATTAAG
G-597A NC_000007.13:g.22766221A>G/
NM_000600.3:c.-116-545A>G
F – forward; R – reverse  
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the GG genotype, 527+461+66 for the GA genotype and 
461+66 for the AA genotype.
Statistical analysis
The differences in genotype and allele distributions be-
tween patients and controls, and groups stratified within 
the patient group, were analyzed with the Pearson chi-
squared test or Fisher’s exact test, when appropriate. The 
consistency of genotype distributions with Hardy-Wein-
berg equilibrium was tested using Pearson chi-squared 
test, for each cohort. All of the tests were 2-sided and dif-
ferences were considered to be significant in all cases when 
p<0.05. Data was analyzed using the SPSS for Windows 
20.0 software (SPSS, Inc, Chicago, IL, USA). Values of link-
age disequilibrium (D', LOD, r2) between polymorphisms 
were tested using the Haploview software, Version 4.2 [16].
rESuLTS
Incidence of polymorphisms among patient and 
control groups
Genotype and allele distributions of all analyzed genes in 
the patient and the control groups are presented in Table 2.
TLR4
The comparison of genotype and allele frequencies among 
patients and controls did not reveal any significant differ-
ences for TLR4 analyzed polymorphisms. Also, genotype 
distributions for patient and control groups were in Har-
dy-Weinberg equilibrium (data not shown). TLR4 poly-
morphisms Asp299Gly and Thr399Ile were in complete 
linkage disequilibrium in both patient and control groups 
(D’=1.0, LOD=15.2, r2=0.92).
IL-6
Complete linkage disequilibrium was observed be-
tween the G-174C and G-597A polymorphisms (D’=1.0, 
LOD=39.92, r2=1.0). All the subjects homozygous 
-174GG were homozygous -597GG, and all the subjects 
homozygous -174CC were homozygous -597AA; conse-
quently, heterozygote subjects at position -174 were in-
variably heterozygous at -597. Therefore, IL-6 G-174C 
and G-597A genotypes and alleles occurred with identical 
frequencies.
Frequencies of alleles -174G/-597G and -174C/-597A 
were similar in patient and control groups, thus no sig-
nificant difference was detected (p=0.51). Also, com-
parison of genotypes according to the presence of allele 
G (-174GG/-597GG and -174GC/-597GA vs. -174CC/-
597AA) among patients and controls did not show any 
significant difference (p=0.50). However, the frequency 
of IL-6 heterozygotes (-174GC/-597GA) was higher, while 
the frequencies of both homozygotes (-174GG/-597GG 
and -174CC/-597AA) were lower in controls compared 
with patients and this difference was statistically signifi-
cant (p=0.047) (Table 3). Thus, according to these results, 
carriers of heterozygote genotype IL-6 -174GC/-597GA 
have 2.49 fold decreased risk of developing Perthes dis-
Table 2. Genotype and allele distributions among Perthes patients and controls (statistical method: Pearson chi-squared test)
Gene variant Genotype Perthes patients
n=37 (frequency)
Controls
n=50 (frequency) OR (95% CI)* p*
TLR4
Asp299Gly
Asp/Asp 30 (0.81) 45 (0.90)
2.10 (0.61–7.24) 0.23 Asp/Gly 6 (0.16) 5 (0.10)
Gly/Gly 1 (0.03) 0 (0.00)
Allele frequency
Asp 0.89 0.95
2.30 (0.72–7.35) 0.15
Gly 0.11 0.05
TLR4
Thr399Ile
Thr/Thr 29 (0.78) 45 (0.90)
2.48 (0.74–8.33) 0.13 Thr/Ile 7 (0.19) 5 (0.10)
Ile/Ile 1 (0.03) 0 (0.00)
Allele frequency
Thr 0.88 0.95
2.63 (0.84–8.20) 0.09
Ile 0.12 0.05
IL-6
G-174C
GG 19 (0.51) 18 (0.36)
0.69 (0.23–2.05) 0.50 GC 10 (0.27) 24 (0.48)
CC 8 (0.22) 8 (0.16)
Allele frequency
G 0.65 0.60
0.81 (0.43–1.51) 0.51
C 0.35 0.40
IL-6
G-597A
GG 19 (0.51) 18 (0.36)
0.69 (0.23–2.05) 0.50 GA 10 (0.27) 24 (0.48)
AA 8 (0.22) 8 (0.16)
Allele frequency
G 0.65 0.60
0.81 (0.43–1.51) 0.51
A 0.35 0.40
n – number of patients; OR – odds ratio; CI – confidence interval
* Shown OR and p-values refer to the following comparisons: TLR4 Asp299Gly- Asp/Asp vs. Asp/Gly + Gly/Gly, TLR4 Thr399Ile- Thr/Thr vs. Thr/Ile + Ile/Ile, IL-6 
G-174C- GG+GC vs. CC, IL-6 G-597A- GG+GA vs. AA     
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ease (OR=2.49, 95% CI=1.00-6.21) (Table 3). Moreover, 
the patient group was not in Hardy-Weinberg equilibrium 
for IL-6 G-174C/G-597A polymorphisms. There were 
more both homozygotes (-174GG/-597GG and -174CC/-
597AA) and less heterozygotes (-174GC/-597GA) ob-
served than expected in this group (p=0.01). In contrast 
to these results, the control group was in complete Har-
dy-Weinberg equilibrium, i.e. the observed values were 
identical to those expected. The fact that only the patient 
group was in Hardy-Weinberg disequilibrium, due to het-
erozygote under representation, supports our finding that 
heterozygotes have a lower chance for the development of 
Perthes disease. These results suggest protective role of 
well-balanced plasma levels of IL-6 protein in the develop-
ment of Perthes disease.
Incidence of polymorphisms and age of  
disease onset
Perthes patients were stratified into two groups: one, with 
early disease onset (younger than five years) and the other, 
with late disease onset (older than five years). Comparison 
of genotype and allele frequencies among these two groups 
did not show significant difference for any of the analyzed 
genes (Table 4).
DISCuSSION
The initiating insult triggering the onset of Perthes dis-
ease remains unknown. It is generally accepted that the 
disruption of blood supply to the femoral head is a key 
pathogenic event, followed by pathological and subsequent 
structural changes to the growing femoral head [17]. Well 
accepted stages of the pathogenesis of the disease are: 
synovitis, condensation, fragmentation (resorption), re-
ossification and healed femoral head [18]. During the frag-
mentation phase, there is a lot of necrotic bone resorption 
and not enough new bone formation. Imbalance between 
bone resorption and bone formation plays an important 
role in the development of severe deformity of the affected 
hip [1]. The inflammatory changes in Perthes disease are 
most marked during the fragmentation phase when bone 
remodeling is unbalanced [9, 10].
Based on the knowledge gained from rheumatoid ar-
thritis and osteoporosis research, that inflammatory cy-
tokines inhibit bone formation and stimulate resorption 
[19, 20], it is possible that the same mechanism could be 
responsible for disturbed bone formation seen in Perthes 
disease. For that reason, the aim of this study was to in-
vestigate the association of Perthes disease with the oc-
currence of different genetic variants of immune response 
genes TLR4 and IL-6.
Table 3. Heterozygote/homozygote ratio for IL-6 G-174C/G-597A
Gene variant of IL-6 Perthes patients
n=37 (frequency)
Controls
n=50 (frequency) OR (95% CI) p
GC/GA 10 (0.27) 24 (0.48)
2.49 (1.00-6.21) 0.047
GG/GG + CC/AA 27 (0.73) 26 (0.52)
Statistical method: Pearson chi-squared test
Table 4. Genotype and allele distributions among Perthes patients with early and late onset
Gene variant Genotype Age at onset ≤5
n=20 (frequency)
Age at onset >5
n=17 (frequency) OR (95% CI)* p* Statistical method
TLR4
Asp299Gly
Asp/Asp 16 (0.80) 14 (0.82)
1.17 (0.22–6.14) 1.00 Fisher’s exact test Asp/Gly 3 (0.15) 3 (0.18)
Gly/Gly 1 (0.05) 0 (0.00)
Allele frequency
Asp 0.87 0.91
1.48 (0.33–6.69) 0.72 Fisher’s exact test
Gly 0.13 0.09
TLR4
Thr399Ile
Thr/Thr 15 (0.75) 14 (0.82)
1.56 (0.31–7.75) 0.70 Fisher’s exact test Thr/Ile 4 (0.20) 3 (0.18)
Ile/Ile 1 (0.05) 0 (0.00)
Allele frequency
Thr 0.85 0.91
1.82 (0.41–7.92) 0.50 Fisher’s exact test
Ile 0.15 0.09
IL-6
G-174C
GG 10 (0.50) 9 (0.53)
2.36 (0.47–11.82) 0.43 Fisher’s exact test GC 7 (0.35) 3 (0.18)
CC 3 (0.15) 5 (0.29)
Allele frequency
G 0.67 0.62
0.77 (0.30–2.05) 0.6 Pearson chi-squared test
C 0.33 0.38
IL-6
G-597A
GG 10 (0.50) 9 (0.53)
2.36 (0.47–11.82) 0.43 Fisher’s exact test GA 7 (0.35) 3 (0.18)
AA 3 (0.15) 5 (0.29)
Allele frequency
G 0.67 0.62
0.77 (0.30–2.05) 0.6 Pearson chi-squared test
A 0.33 0.38
* Shown OR and p-values refer to the following comparisons: TLR4 Asp299Gly- Asp/Asp vs. Asp/Gly + Gly/Gly, TLR4 Thr399Ile- Thr/Thr vs. Thr/Ile + Ile/Ile, IL-6 G-174C- 
GG+GC vs. CC, IL-6 G-597A- GG+GA vs. AA     
doi: 10.2298/SARH1408450S
454
TLR4 is one of the most important pathogen recogni-
tion receptors that is activated by lipopolysaccharide (LPS) 
of Gram-negative bacteria [21]. Using the rat model sys-
tem, it has been shown that femoral head osteonecrosis 
can be induced by treatment with LPS and methylpred-
nisolone, through TLR4 signaling pathway, which includes 
the regulation of cytokine IL-6 [22].
The TLR4 gene has two important non-synonymous 
polymorphisms that lead to impaired TLR4 response and 
the altered expression of cytokines regulated by this recep-
tor [23]. These are an A/G transition causing an aspartic 
acid/glycine substitution at amino acid position 299 (As-
p299Gly), and a C/T transition causing a threonine/isoleu-
cine change at 399 (Thr399Ile). These two polymorphisms 
cosegregated in our patient and control groups, which is 
consistent with the results of other studies [24, 25].
We proposed that TLR4 Asp299Gly and Thr399Ile pol-
ymorphisms, and their effects on immune gene expression 
might change bone turn-over against bone formation and 
influence the development of Perthes disease, but we did 
not find any significant association of these two polymor-
phisms with this disease.
IL-6 is a cytokine with diverse functions, including the 
major role in the regulation of bone metabolism [19]. Dys-
regulated IL-6 production is implicated in the pathology of 
several diseases. Increased IL-6 levels are characteristic of 
systemic onset juvenile chronic arthritis [26], rheumatoid 
arthritis [27] and osteoporosis [28].
IL-6 is not constitutively expressed, but is highly induc-
ible and is produced in response to a number of inflamma-
tory stimuli such as IL-1, platelet-derived growth factor, 
TNF-a, bacterial products and viral infection [29]. Circu-
lating levels of IL-6 are mainly regulated at the level of gene 
expression [30] that is tightly controlled by co-ordination 
among various transcription factors [31]. Polymorphisms 
in the promoter region of IL-6 gene, in particular SNPs 
at positions G-174C and G-597A that are involved in the 
transcriptional regulation of the IL-6 gene, have been re-
ported to be associated with plasma levels of IL-6 and with 
the risk of several bone and joint diseases [26, 32, 33].
Analyzed polymorphisms in IL-6 gene (G-174C and G-
597A) were in linkage disequilibrium in both the patient 
and control groups, which is consistent with the results of 
other studies [15, 32, 33].
We found that IL-6 heterozygotes were significantly 
overrepresented in the controls compared to the patients. 
Also, Perthes patients were not in Hardy-Weinberg equi-
librium, in contrast to the control subjects, which were 
in complete equilibrium. The genotype distribution of 
our control population resembled that of white control 
populations investigated by others [26, 33]. Thus, our re-
sults suggest that carriers of heterozygote genotypes IL-6 
-174GC/-597GA have a smaller chance of developing 
Perthes disease than carriers of both types of homozygote 
genotypes (-174GG/-597GG and -174CC/-597AA).
The heterozygote advantage of the IL-6 G-174C/G-597A 
polymorphisms has not been described before. Controver-
sial data came from the studies that correlated IL-6 -174 
homozygote GG genotype and/or presence of G allele and 
homozygote CC genotype with IL-6 plasma levels [26, 34-
36], as well as with the bone quality [33, 37]. Dual roles of 
IL-6 could be a possible explanation for heterozygote advan-
tage, since both the proinflammatory and antiinflammatory 
effects of IL-6 have been well described [38]. Because IL-6 
is a pleiotropic cytokine involved in immune response and 
bone remodeling, heterozygote advantage might be the re-
sult of the better balancing of these processes.
CONCLuSION
To the best of our knowledge, this is the first report re-
garding the genetic aspect of inflammatory mediators in 
Perthes patients. Comparison of genotype distribution 
between the control and Perthes patient groups revealed 
that heterozygote subjects for the IL-6 G-174C/G-597A 
polymorphisms were significantly overrepresented in the 
control group. Consequently, we concluded that children 
who are heterozygous for these polymorphisms have a 
lower chance of developing Perthes disease than carri-
ers of both homozygote genotypes. This finding points to 
the importance of well-balanced IL-6 protein level in the 
regulation of inflammatory process in Perthes disease. Al-
though our results need to be confirmed in larger groups, 
they represent new and interesting findings and we believe 
that they could contribute to the understanding of the as-
sociation of Perthes disease with genetic heterogeneity in 
immune response genes.
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КРАТАК САДРЖАЈ
Увод Пер  те  со  ва бо  лест је иди  о  пат  ска ава  ску  лар  на осте  о-
не  кро  за прок  си  мал  не епи  фи  зе фе  му  ра ко  ја се ја  вља код 
де  це. Ети  о  ло  ги  ја ове бо  ле  сти је не  по  зна  та. То  ком раз  во  ја 
Пер  те  со  ве бо  ле  сти за  сту  пљен је про  цес запаљења, за ко-
ји је по  ка  за  но да ути  че на ре  мо  де  ло  ва  ње ко  шта  ног тки  ва.
Циљ ра  да С об  зи  ром на то да ге  не  тич  ки фак  то  ри ко  ји ути-
чу на про  цес за  па  ље  ња до  сад ни  су ис  пи  ти  ва  ни код Пер  те-
со  ве бо  ле  сти, циљ овог ис  тра  жи  ва  ња је био да се утвр  ди 
по  ве  за  ност уче  ста  ло  сти ва  ри  јан  ти у ге  ни  ма ко  ји уче  ству  ју 
у ин  фла  ма  тор  ном од  го  во  ру, TLR4 (енгл. toll-li ke re cep tor 4) и 
IL-6 (ин  тер  ле  у  кин 6), и ове бо  ле  сти.
Ме  то  де ра  да Ис  пи  та  но је 37 де  це с Пер  те  со  вом бо  ле  шћу 
и 50 здра  вих особа. Ме  то  дом PCR-RFLP од  ре  ђе  ни су по  ли-
мор  фи  зми ме  ди  ја  то  ра за  па  ље  ња TLR4 (Asp299Gly, Thr399Ile) 
и IL-6 (G-174C, G-597A).
Ре  зул  та  ти По  ка  за  но је да су по  ли  мор  фи  зми IL-6 G-174C 
и G-597A у на  шем ис  пи  ти  ва  њу би  ли у пот  пу  ној га  мет  ској 
не  рав  но  те  жи ве  за  но  сти. У кон  трол  ној гру  пи је би  ло ста-
ти  стич  ки зна  чај  но ви  ше но  си  ла  ца хе  те  ро  зи  гот  ног ге  но  ти-
па IL-6 G-174C/G-597A у по  ре  ђе  њу са гру  пом ис  пи  та  ни  ка с 
Пер  те  со  вом бо  ле  шћу (p=0,047; OR=2,49; 95% CI=1,00–6,21). 
Та  ко  ђе, гру  па бо  ле  сни  ка ни  је би  ла у Хар  ди–Вајн  бер  го  вој 
рав  но  те  жи за по  ли  мор  фи  зме IL-6 G-174C/G-597A. Ни  је при-
ме  ће  на ста  ти  стич  ки зна  чај  на раз  ли  ка у рас  по  де  ли ге  но  ти-
по  ва за по  ли  мор  фи  зме ана  ли  зи  ра  не у TLR4 ге  ну. Рас  по  де  ла 
ге  но  ти  по  ва ме  ђу гру  па  ма бо  ле  сни  ка фор  ми  ра  них на осно  ву 
уз  ра  ста ка  да се бо  лест по  ја  ви  ла ни  је по  ка  за  ла ста  ти  стич-
ки зна  чај  ну по  ве  за  ност с ана  ли  зи  ра  ним по  ли  мор  фи  зми  ма.
За  кљу  чак На  ше ис  тра  жи  ва  ње је по  ка  за  ло да су но  си  о  ци хе-
те  ро  зи  гот  ног ге  но  ти  па за IL-6 G-174C/G-597A по  ли  мор  фи  зме 
би  ли зна  чај  но че  шћи у кон  трол  ној гру  пи не  го у гру  пи де  це 
обо  ле  ле од Пер  те  со  ве бо  ле  сти. На осно  ву то  га за  кљу  чи  ли 
смо да је код де  це ко  ја су но  си  о  ци хе  те  ро  зи  гот  ног ге  но  ти  па 
за ове по  ли  мор  фи  зме ма  ња ве  ро  ват  но  ћа за раз  вој Пер  те-
со  ве бо  ле  сти не  го код но  си  ла  ца оба хо  мо  зи  гот  на ге  но  ти  па.
Кључ  не ре  чи: ген  ске ва  ри  јан  те; ин  фла  ма  ци  ја; Пер  те  со  ва 
бо  лест
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